Advertisement
Product › Details
EOS884448 (anti-TIGIT antibody, iTeos Therapeutics)
Next higher product group | antibody cancer drug | |
Status | 2018-06-20 development pp existent | |
Organisation | iTeos Therapeutics S.A. | |
Group | iTeos Therapeutics (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for EOS884448 (anti-TIGIT antibody, iTeos Therapeutics)
- [1] iTeos Therapeutics Inc.. (6/14/21). "Press Release: iTeos Therapeutics and GSK Announce Development and Commercialisation Collaboration for EOS-448, an anti-TIGIT Monoclonal Antibody, Enabling Novel Next-generation Immuno-oncology Combinations". Gosselie...
- [2] iTeos Therapeutics Inc.. (4/1/20). "Press Release: iTeos Therapeutics Closes $125 Million Series B2 Financing". Cambridge, MA & Gosselies....
- [3] iTeos Therapeutics S.A.. (2/27/20). "Press Release: iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers". Cambridge, MA & Gosselies....
- [4] iTeos Therapeutics S.A.. (1/30/20). "Press Release: iTeos Therapeutics Awarded €15 Million in Non-Dilutive Funding by the Walloon Region". Gosselies & Cambridge, MA....
- [5] iTeos Therapeutics S.A.. (7/3/18). "Press Release: iTeos Therapeutics Appoints Scott Chappel as Chief Scientific Officer". Gosselies....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top